{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'INCREASE IN ALT', 'COMPLETE the specific CRF forms', 'ALT > 3 ULN', 'for \"ALT Increase\" and inform the', 'Monitoring Team within 24 hours', 'Confirm ALT> 3 ULN', 'Retest within 72 hours of initial sample*', 'ALT <5 ULN', 'ALT: > 3 ULN &', 'Total Bilirubin > 2 ULN', 'Monitor LFTs every 72 hours', 'ALT: > 5 ULN', 'IMP administration can be continued as', 'long as - under close monitoring -', 'Permanent Discontinuation of IMP', 'conditions for permanent', 'discontinuation or temporary', 'interruption per protocol are not met', 'In ANY CASE, FOLLOW the instructions listed in the box below:', '1. INFORM the Site Monitor who will forward the information to the Study Manager', '2. INVESTIGATE specifically for malaise with or without loss of consciousness, dizziness, and/or', 'hypotension and/or episode of arrhythmia in the previous 72 hours; rule out muscular injury', '3. PERFORM the following tests:', '- LFTs: AST, ALT, alkaline phosphatase, total and conjugated bilirubin and prothrombin time / INR', '- CPK, serum creatinine, complete blood count', '- Anti-HAV IgM, anti-HBc IgM, (HBV-DNA if clinically indicated), anti-HCV and HCV RNA, anti-', 'CMV IgM and anti-HEV IgM antibodies', '- Depending on the clinical context, check for recent infection with EBV, herpes viruses, and toxoplasma', '- Hepatobiliary ultrasonography (or other imaging investigations if needed)', '4.', 'CONSIDER Auto-antibodies: antinuclear, anti-DNA, anti-smooth muscle, anti-LKM', '5.', 'CONSIDER consulting with hepatologist', '6.', 'CONSIDER patient hospitalisation if INR>2 (or PT<50%) and/or central nervous system disburbances', 'suggesting hepatic encephalopathy', '7.', 'MONITOR LFTs after discontinuation of IMP:', '- As closely as possible (or every 48 hours) until stabilization, then every 2 weeks until return to', 'normal/baseline or clinical resolution.', '8. FREEZE serum sample (5ml x 2)', '9. In case of SUSPICION of GILBERT Syndrome, a DNA diagnostic test should be done', '*If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation.', 'Note:', '\"Baseline\" refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the', 'baseline visit. The algorithm does not apply to the instances of increase in ALT during screening.', 'See Section 10.4 for guidance on safety reporting.', 'Normalization is defined as < ULN or baseline value, if baseline value is >ULN.', 'Property of the Sanofi Group - strictly confidential', 'Page 99', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'ACUTE RENAL FAILURE', 'Rapid increase in serum creatinine over 150 mol/L', 'or rapid decrease in creatinine clearance below', '50 mL/mn', 'Can be rapidly reversed:', 'Cannot be rapidly reversed:', 'By volume repletion', 'Occurrence/aggravation of life', 'Or relief of urinary tract', 'threatening symptoms of ARF: anemia,', 'obstruction (according to etiology)', 'hyperkalemia, hyperuricemia, metabolic', 'acidosis, cardiac insufficiency,', 'pulmonary edema, arrhythmia, DIC, etc.', 'And/or predominant elimination of', 'Investigational Medicinal Product by', 'renal route', '1.', 'INFORM the local monitor', '2.', 'DISCONTINUE', '1.', 'Investigational Medicinal', 'Investigational Medicinal Product', 'Product may be continued', 'administration', '2.', 'MONITOR serum creatinine', '3.', 'HOSPITALIZATION should be', 'until return to baseline level', 'considered and seek for nephrologic', 'advice', '4.', 'PERFORM the following', 'examinations:', 'BP, HR, hydration status, ECG', 'Blood count', 'Liver function tests + CPK', 'Biochemistry, including urea', 'Urinalysis', '5.', 'COLLECT/STORE one sample', 'following handling procedures', 'described in PK sections (for studies', 'with PK sampling) and freeze one', 'serum sample (5 mL) on Day 1', '(cessation of investigational', 'medicinal product)', '6.', 'MONITOR renal function until', 'return to baseline level (every day at', 'the beginning, then every week)', 'Acute renal failure is to be recorded as an AE only if at least 1 of the criteria listed in the general', 'guidelines for reporting adverse events in Section 10.4.3 is met.', 'Property of the Sanofi Group - strictly confidential', 'Page 100', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}